Drugmaker Tergacept's experimental ADHD medication is being moved into late-stage clinical trails, according to the company. The drug--known as AZD3480 or TC-1734--has already completed mid-stage trials for ADHD, as well as for Alzheimer's and Schizophrenia. The medication is part of a new class of drugs called neuronal nicotinic receptor therapeutics, which are aimed at treating central nervous system disorders.
Read moreDeciding to medicate your ADHD child is never an easy decision for parents. Hearing rants from anti-drug groups claiming that stimulants... Read more »
A new statement from the American Heart Association is quite explicit: Before you give kids stimulant meds for ADHD, make sure their heart... Read more »
Drugmaker Shire reports that an experimental medication significantly reduced defiant, angry behavior in kids with ADHD in a recent study. The... Read more »
Drugmaker Targacept Inc. says their experimental adult ADHD medication has met its primary target in a Phase II clinical trial. The... Read more »
A study found new treatments for attention-deficit/hyperactivity disorder are less likely to be abused because of the way the medications are... Read more »
This national clinical trial is recruiting children ages six to 12 to test a new medication for attention-deficit/hyperactivity disorder.... Read more »
Shire reports that the Food and Drug Administration has issued an approvable letter for SPD465, its proposed attention-deficit/hyperactivity... Read more »